Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

NCT04129099 is registered in ClinicalTrials.gov with Hebei Yanda Ludaopei Hospital as lead sponsor.

NCT NCT04129099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04129099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Lead sponsor
Hebei Yanda Ludaopei Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
October 22, 2019
Completion date
June 30, 2022
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia